Márton Vámosi

Márton Vámosi

Auto-generated profile, based on publicly available information

Márton Vámosi

Momentum Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSusanne Prokop
Susanne Prokop
Peter Ábrányi-BaloghPeter Ábrányi-Balogh
Peter Ábrányi-Balogh
BBBenjámin Barti
Benjámin Barti
MVMárton Vámosi
Márton Vámosi
MZMiklós Zöldi
Miklós Zöldi
IKIstván Katona
István Katona
Immunolabeling and autoradiography have traditionally been applied as the methods-of-choice to visualize and collect molecular information about physiological and pathological processes. Here, we introduce PharmacoSTORM super-resolution imaging that combines the complementary advantages of these approaches and enables cell-type- and compartment-specific nanoscale molecular measurements. We exploited rational chemical design for fluorophore-tagged high-affinity receptor ligands and an enzyme inhibitor; and demonstrated broad PharmacoSTORM applicability for three protein classes and for cariprazine, a clinically approved antipsychotic and antidepressant drug. Because the neurobiological substrate of cariprazine has remained elusive, we took advantage of PharmacoSTORM to provide in vivo evidence that cariprazine predominantly binds to D3 dopamine receptors on Islands of Calleja granule cell axons but avoids dopaminergic terminals. These findings show that PharmacoSTORM helps to quantify drug-target interaction sites at the nanoscale level in a cell-type- and subcellular context-dependent manner and within complex tissue preparations. Moreover, the results highlight the underappreciated neuropsychiatric significance of the Islands of Calleja in the ventral forebrain.